Satralizumab|cas:1535963-91-7|西域试剂

Satralizumab,99.82%

产品编号：Bellancom-P99112| CAS NO：1535963-91-7

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99112		￥6400.00	杭州北京（现货）
Bellancom-P99112		￥14000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Satralizumab

产品介绍

Satralizumab 是一种人源化单克隆抗体，是一种有效的白细胞介素 -6 (IL-6) 抑制剂。Satralizumab 可防止褐家鼠的 dTAA 形成和发展。Satralizumab 可用于视神经脊髓炎 (NMOSD) 和降胸主动脉动脉瘤 (dTAA) 的研究。

生物活性

Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research.

体外研究

体内研究

Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rattus norvegicus (forty, male, 10-week-old, four equal groups)
Dosage:	120 mg
Administration:	Subcutaneously, once every 2 weeks, for 4 weeks
Result:	Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.

体内研究

Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rattus norvegicus (forty, male, 10-week-old, four equal groups)
Dosage:	120 mg
Administration:	Subcutaneously, once every 2 weeks, for 4 weeks
Result:	Prevented dTAA (descending thoracic aorta aneurysm) formation and progression.